Safety and efficacy of zoledronic acid in multiple myeloma

The Lancet

Volumn 377, Issue 9784, 2011, Pages 2178-

  Tanimoto, Tetsuya ^a   Matayoshi, Tetsutaro ^b   Yagasaki, Fumiharu ^c   Takeuchi, Kengo ^a   Kami, Masahiro ^d  

^a CANCER INSTITUTE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLODRONIC ACID; DEXAMETHASONE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; WARFARIN; ZOLEDRONIC ACID;

CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

EID: 79959745551     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60959-8     Document Type: Letter

References (5)

1. GJ Morgan, FE Davies, WM Gregory et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 2010 1989 1999
2. GH Lyman, AA Khorana, A Falanga et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 2007 5490 5505 (Pubitemid 350232226)
3. GH Lyman, AA Khorana Cancer, clots and consensus: new understanding of an old problem J Clin Oncol 27 2009 4821 4826
4. A Falanga, M Marchetti Venous thromboembolism in the hematologic malignancies J Clin Oncol 27 2009 4848 4857
5. A Palumbo, SV Rajkumar, MA Dimopoulos et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423 (Pubitemid 351255436)